Exelixis ((EXEL)), Novartis AG ((NVS)), Bristol-Myers Squibb Company ((BMY)), Clovis Oncology Inc ((CLVSQ)), DEL_Novartis (0QM7) ((DEL_0QM7)), DEL_Novartis Inc ((DEL_0QLR)), Novartis ((CH:NOVN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The Pan-Tumor Rollover Study, officially titled ‘Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies,’ aims to evaluate the long-term safety of nivolumab monotherapy and its combinations with other cancer therapies across various tumor types. This study is significant as it explores sustained treatment options for patients who have previously participated in Bristol-Myers Squibb (BMS) trials.
The study tests several experimental interventions, including nivolumab alone and in combination with drugs like ipilimumab, cabozantinib, and relatlimab. These treatments target different cancer pathways to improve patient outcomes.
Designed as a non-randomized, parallel assignment, the study focuses on treatment as its primary purpose. There is no masking involved, allowing for open observation of treatment effects.
The study began on August 9, 2019, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on August 14, 2025, indicating ongoing progress.
This study update could influence the stock performance of involved companies like Bristol-Myers Squibb, Exelixis, and Novartis. Positive results may boost investor confidence and share prices, especially in a competitive oncology market.
The study is ongoing, with further details available on the ClinicalTrials portal.